The global eosinophilic esophagitis market is expected to reach at USD 172.2 Billion in 2023 and is projected to exhibit a CAGR of 28% from 2022 to 2032. Over the forecast period, the market is projected to grow at a rapid rate due to factors such as increased awareness programs for disorders associated with Eosinophils.
A new generation of non-invasive diagnostic tools is emerging. A minimally invasive method for diagnosing EoE and assessing disease activity has been proposed due to the invasive nature of repetitive endoscopic evaluation with multiple biopsies.
The worldwide EoE market is growing rapidly due to the increasing use of eosinophilic esophagitis drugs and therapies for the treatment of numerous inflammations in developed nations. For instance, European officials recently approved a budesonide effervescent tablet formulated especially for EoE, which optimizes mucosal deposition.
Women and men can both be affected by EoE, but men in their 30s and 40s are most likely to be affected. According to current estimates, one in 2000 Americans suffer from EoE, and there is evidence to suggest that the number is on the rise. There has been an upward trend in the number of new cases of EoE globally over the last few decades, especially since the early 2000s, in a review of over 30 European and North American studies.
For instance, the FDA has approved dupilumab, the first therapy specifically for EoE. Two parallel-group, randomized, double-blind, multicenter, placebo-controlled, randomized evaluations of safety and efficacy were conducted with approval from the FDA during the study.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2022) | USD 140 Billion |
| Expected Market Value (2023) | USD 172.21 Billion |
| Anticipated Forecast Value (2033) | USD 2,032.8 Billion |
| Projected Growth Rate (2023 to 2033) | 28% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for eosinophilic esophagitis is projected to increase at a CAGR of 28% during the forecast period between 2023 and 2033, reaching a total of USD 2,032.8 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 23%.
In the past decade, advances in EoE diagnosis have included endoscopic functional lumen imaging probes (FLIP), transnasal endoscopy (TNE), and noninvasive test methods such as mucosal impedance probes, EoE cytosponge, and esophageal string tests. There has not been clinical evidence to support biomarkers for EoE. EoE continues to evolve with the development of new diagnostic algorithms, treatment modalities, and noninvasive diagnostic methods. In order to manage EoE patients effectively, multimodal and multidisciplinary approaches are still required.?
Increasing public-private subsidies are expected for target investigation activities, the demand for minimally invasive surgery will increase, the number of children participating in sports will increase, and as technology advances throughout the world, new product inventions and developments will increase the profits for market players. As the internet diffusion rate increases, arthroscopic surgeries are increasingly implemented, and the elderly and obese population are growing throughout the world, the market is expected to expand at a higher rate in future years.
Extensive Uptake during the Pandemic Crisis for Developing Drugs provided a Major Boost in past years
Increasing awareness of EoE and conditions are expected to grow the market in the near future. In order to spread awareness of eosinophil-associated complaints, numerous awareness plans have been developed and implemented, which are predicted to drive market growth over the forecast period. As a non-profit organization, the American Enterprise for Eosinophilic Disorders (APFED) educates, hovers consciousness, supports, and advocates for patients and families dealing with eosinophil-associated conditions.?
Increasing funding for Research and Development programs and the development of new treatments for EoE is expected to further drive the market's growth in the future. As new technologies and drug delivery methods are developed in the coming years, it is expected that the market will continue to grow in the future. EGD requires invasive procedures for monitoring and diagnosis, so offices are seeking minimally invasive tests and noninvasive biomarkers.
Numerous New Initiatives Offer Lucrative Opportunities to Treat Eosinophilic Esophagitis
Market players are also taking strategic initiatives to develop products for eosinophilic esophagitis and market them effectively. As well, several new drugs are being developed for the treatment of inflammatory conditions of the esophagus. For example, Jorveza (budesonide), a medicine for treating eosinophilic oesophagitis, a condition affecting the esophagus, was recommended for marketing authorization by the European Medicines Agency (EMA).
Similarly, in December 2022, a professor of medicine at the University of Toronto who heads the Center for Esophageal Diseases and Swallowing, Prof. Evan Dellon, MD, MPH, will be leading an effort to get an allergy medicine, dupilumab, approved to treat high-grade eosinophilic esophagitis in adults and adolescents.
Principal Consultant
Economic Costs of Eosinophilic Esophagitis Impede Growth?
Market growth is expected to be hindered by regulatory approval challenges over the forecast period. Regulation authorities require a lot of effort and time to approve the drug, as regulatory authorities such as the USA Food and Drug Administration (FDA) companies that develop, manufacture, market, and distribute drugs face substantial and burdensome requirements.
Eosinophilic esophagitis is not widely understood and improper treatment can further harm the market if it is not treated timely. As a result of the high cost of treatment and the lack of information provided to patients, the eosinophilic esophagitis market in various regions has been constrained.
Healthcare Sector Expansion Boosts Eosinophilic Esophagitis Adoption
With an established healthcare infrastructure, high patient awareness, and growing EoE research prospects, North America held the biggest market share of 33% in 2023. There is an increase in demand for advanced treatments in North America, a rise in health care expenditures, and a high level of diagnosis in the region which contributes to the growth of this market. Because there is no FDA-approved drug for EoE and the burden of EoE has been increasing over the past few years, there is intense competition between market players to get a first-mover advantage.
According to the USA Government, about 160,000 people in the country suffer from eosinophilic esophagitis, which is treated with off-label drugs that have not been approved by the FDA, and dietary modifications. Healthcare costs associated with EoE in the United States alone are approximately USD 1.6 billion annually.
APFED (American Partnership for Eosinophilic Disorders) and Rare Diseases Clinical Research Network (CEGIR) are two organizations that provide research grants and funding, particularly in developed economies. For instance, The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American Academy of Pediatrics and Pediatric Feeding Disorders (APFED) have awarded USD 140,000 for a two-year study to investigate to what extent the immune system interacts with foods that cause food allergy reactions. Moreover, the research will play a significant role in the identification of future drug targets as well as disease pathogenesis.
New Drugs and Medical Infrastructure are propelling Eosinophilic Esophagitis Treatment Demand in Europe?
As the forecast period continues to unfold, the Europe region is projected to exhibit the fastest growth rate due to the increasing disposable incomes, the large population of patients who suffer from EoE Oesophagitis, and an increased focus on healthcare during the forecast period.
Research and development prospects are expected to be positively affected by countries such as the UK that offer attractive investment opportunities for clinical research. For instance, EsoCap supports the first Europe EoE Day in May 2022 of the European Society of Eosinophilic Oesophagitis. EoE diagnosis and treatment pathways are the focus of the campaign, which is the first of its kind in Europe. Increasing public awareness will increase screening and better diagnosis rates, which are critical for effectively treating EoE since early intervention is key.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Patients with GERD Disease are expected to Increase PPI Production at a Significant Rate
In the field of gastroesophageal reflux disease (GERD), proton pump inhibitors are the gold standard medication. Various factors are driving the growth of this market, including an increase in GERD cases, the acceptance of new drug delivery systems, as well as the growth in proton pump inhibitor sales. A rise in the prevalence of gastrointestinal disorders, including barrettes esophagus, duodenal ulcers, and non-erosive reflux disease (NERD), is likely to fuel the market growth for proton pump inhibitors in the coming years.
In the last few years, proton pump inhibitors have become more widely prescribed in ambulatory settings in the US. The marketing of brands is also a major expense for many firms. The American Board of Internal Medicine has also acknowledged the widespread use of PPIs; therefore, a campaign was launched to promote their appropriate use. Furthermore, the market will also be affected by product launches in a generic category. For instance, Hanmi Pharmaceutical aims to address the gastritis treatment market with Esomezol DR SR Cap. 10 mg (esomeprazole magnesium trihydrate), or Esomezol DR 10 mg, which was released recently. Watchers of the industry pay attention to which medicine or component will prevail in the fierce competition over gastritis treatments.
Demand for Eosinophilic Esophagitis in Hospital Pharmacies to Gain Traction
EoE treatments for GERD are becoming increasingly popular in hospitals, which is leading to a 42.1% market share in 2023. It is expected that the segment will continue to dominate during the forecast period due to rising healthcare expenditures globally, growing patient awareness levels, and advanced hospital infrastructure in developed countries.
A tenfold increase in EoE-related hospitalizations from 2010 to 2016 has been observed in US hospital admission rates, along with an associated increase in mean costs. The high risk of side effects and risks associated with medicines may further increase the market sales of medicines in hospital pharmacies.
Some of the start-ups in the eosinophilic esophagitis market? include?
Manufacturers can increase production and meet consumer demand with strategic partnerships, boosting revenue and market share. End users will benefit from natural drugs for the treatment of EoE by leveraging new products and technologies. Strategic partnerships can help companies expand their production capabilities.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 172.21 Billion |
| Market Value in 2033 | USD 2,032.8 Billion |
| Growth Rate | CAGR of 28% from 2022 to 2032 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Ellodi Pharmaceuticals; EsoCap AG; GlaxoSmithKline plc.; Teva Pharmaceutical Industries Ltd.; Cipla Limited; Sun Pharmaceutical Industries Limited; AstraZeneca Plc; Sanofi S.A.; Arena Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Revolo Biotherapeutics; Allakos Inc. |
| Customization | Available Upon Request |
FMI projects the global eosinophilic esophagitis market to expand at a 28% value CAGR by 2033.
The global eosinophilic esophagitis market is estimated at a market value of USD 172.21 Billion.
The global eosinophilic esophagitis market is expected to garner a market value of USD 2032.8 Billion.
FMI has projected North America to be one of the key regions for the eosinophilic esophagitis market, with the US expected to account for over 33% of the North American market during the forecast period.
Sanofi S.A., GlaxoSmithKline plc, Cipla Limited, and Teva Pharmaceutical Industries Ltd. are some prominent eosinophilic esophagitis manufacturers.
The PPI drug class held the largest share and accounted for 54% of the market value in 2023.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Corticosteroids 5.1.1. Budesonide 5.1.1.1. Jorveza 5.1.1.2. Off-label budesonide 5.1.2. Fluticasone 5.2. Proton Pump Inhibitor (PPI) 5.2.1. Omeprazole 5.2.2. Esomeprazole 5.2.3. Others 5.3. Late-Stage Pipeline Drugs 5.3.1. Dupixent 5.3.2. APT-1011 5.3.3. Lirentelimab (AK002) 5.3.4. Cendakimab 5.3.5. Etrasimod 5.3.6. TAK-721 5.3.7. Omilancor (BT-11) 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Hospital Pharmacies 6.2. Retail Pharmacies 6.3. Online Pharmacies 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia 7.5. East Asia 7.6. Oceania 7.7. Middle East & Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Ellodi Pharmaceuticals 17.2. EsoCap AG 17.3. GlaxoSmithKline plc. 17.4. Teva Pharmaceutical Industries Ltd. 17.5. Cipla Limited 17.6. Sun Pharmaceutical Industries Limited 17.7. AstraZeneca Plc 17.8. Sanofi S.A. 17.9. Arena Pharmaceuticals, Inc. 17.10. Takeda Pharmaceutical Company Limited 17.11. Revolo Biotherapeutics 17.12. Allakos Inc. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Eosinophilic Esophagitis Market
